Quanterix Submits FDA 510(k) for Multi-Analyte Blood Test for Alzheimer's Disease: QTRX

[Para 1: The Lead] Quanterix Corporation (NASDAQ: QTRX) has submitted a 510(k) pre-market notification to the U.S. Food and Drug Administration (FDA) for its multi-analyte blood test aimed at detecting Alzheimer's disease biomarkers. The submission is expected to expedite the regulatory pathway for the test's market entry, potentially revolutionizing early diagnosis and treatment strategies. [Para 2-3: Supporting details & Context] The test, which analyzes multiple biomarkers in a single blood sample, is designed to provide accurate and reliable results. Quanterix aims to complete the FDA review process by the second quarter of 2026. Financially, the test's approval could significantly boost QTRX's revenue, with market analysts predicting a 20% increase in the company's earnings per share in the fiscal year following approval. The test's potential to reduce healthcare costs and improve patient outcomes is expected to be a key driver for its adoption.